Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-4,199
Closed -$601K 457
2021
Q4
$601K Buy
+4,199
New +$721K 0.06% 82
2021
Q2
Sell
-2,363
Closed -$433K 521
2021
Q1
$428K Sell
2,363
-966
-29% -$192K 0.02% 97
2020
Q4
$371K Sell
3,329
-370
-10% -$39.3K 0.03% 113
2020
Q3
$401K Buy
+3,699
New +$451K 0.03% 69

Other funds holding NVAX

XR Securities's NVAX Position: Q1 2022 in Review

XR Securities sold out of Novavax (NVAX) in Q1 2022, closing a stake of 4,199 shares — an estimated $601K sold.

XR Securities first reported a position in NVAX in Q3 2020 and held it in 4 quarters. The position peaked at $601K in Q4 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

  • XR Securities reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
  • XR Securities sold 4,199 Novavax shares in Q1 2022, an estimated $601K.
  • XR Securities first reported a position in Novavax in Q3 2020 and held it in 4 quarters.
  • XR Securities's Novavax position peaked at $601K in Q4 2021.
  • 381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on XR Securities's 13F filing for Q1 2022, filed 14 Apr 2022.